Ocugen, Inc.

Ocugen (OCGN) shows no cyber incidents or material red-flag 8-K filings in our 90-day detection window. However, the absence of recent signals does not establish baseline risk; the company operates in a capital-intensive biotech segment where financing history, share dilution patterns, and longer-term regulatory developments carry substantial weight. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, maps financing rounds and their terms, and flags AI-detected risk signals across 8-K context and officer movement. The full $49 Report adds dilution trajectory, 12-month 8-K breakdown, capital raise history, and AI risk scoring.